HIGHLIGHTS OF PRESCRIBING INFORMATION	<ul> <li><u>Hepatic Impairment</u>: Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of hepatic impairment. (2.3)</li> </ul>	Intravenous Administration: The initial starting dose is 0.2		
These highlights do not include all the information needed to use DILAUDID® INJECTION safely and effectively. See full prescribing information for DILAUDID® INJECTION.	<u>Renal Impairment</u> : Initiate treatment with one-fourth to one-half the usual starting dose, depending on degree of renal	minutes, depending on the do		
DILAUDID® INJECTION (hydromorphone hydrochloride) for intravenous, intramuscular, or subcutaneous use, CII	impairment. (2.4)	Conversion From Other Opioi		
Initial U.S. Approval: January 1984	Do not stop DILAUDID INJECTION abruptly in a physically-dependent patient (2.6)      DOSAGE FORMS AND STRENGTHS	There is inter-patient variabil is advised when determining		
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS	DILAUDID Injection, 0.5 mg/0.5mL, 1 mg/mL or 2 mg/mL are available in single-dose prefilled syringes. (3)     CONTRAINDICATIONS	DILAUDID INJECTION dosage due to overdose.		
DEPRESSANTS See full prescribing information for complete boxed warning.	Significant respiratory depression. (4)	If the decision is made to convert the		
• DILAUDID INJECTION exposes users to risks of addictions, abuse, and misuse, which can lead to overdose and	Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (4)	available data, convert the c INJECTION and reduce by on		
death. Assess patient's risk before prescribing and monitor regularly for these behaviors and conditions. (5.1)	• Known or suspected gastrointestinal obstruction, including paralytic ileus. (4)	number of doses permitted b		
• Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (5.2)	<ul> <li>Known hypersensitivity to hydromorphone, hydromorphone salts, sulfite-containing medications, or any other components of the product (4)</li> </ul>	the patient's response. 2.3 Dosage Modificatio		
<ul> <li>Prolonged use of DILAUDID INJECTION during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate</li> </ul>	Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated	Start patients with hepatic im extent of impairment [see Cli		
treatment will be available. (5.3)	Patients: Monitor closely, particularly during initiation and titration. (5.5)	2.4 Dosage Modificatio		
<ul> <li>Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing</li> </ul>	<ul> <li><u>Adrenal Insufficiency</u>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (5.6)</li> </ul>	Start patients with renal impa		
for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (5.4, 7).	• <u>Severe Hypotension</u> : Monitor during dosage initiation and titration. Avoid use of DILAUDID INJECTION in patients with	degree of impairment [see Cl		
	circulatory shock. (5.7)	2.5 Titration and Maint Individually titrate DILAUDID		
Boxed Warning, information pertaining to the discontinued product DILAUDID-HP Removed 1/2018	<ul> <li><u>Risks of Use in Patients with Increased Intracranial Pressure</u>, <u>Brain Tumors</u>, <u>Head Injury</u>, <u>or Impaired Consciousness</u>; Monitor for sedation and respiratory depression. Avoid use of DILAUDID INJECTION in patients with impaired consciousness or coma.</li> </ul>	reevaluate patients receiving		
Indications and Usage, information pertaining to DILAUDID-HP (1) Removed 1/2018	(5.8)	adverse reactions, as well as (5.1)]. Frequent communication		
Dosage and Administration, information pertaining to DILAUDID-HP (2) Removed 1/2018	• DILAUDID INJECTION contains sodium metabisulfite. There is a risk of anaphylactic symptoms and life-threatening asthmatic	caregiver/family during period		
Contraindications, information pertaining to DILAUDID-HP (4) Removed 1/2018	episodes in susceptible people (5.13)	If the level of pain increases		
Warnings and Precautions, information pertaining to DILAUDID-HP (5) Removed 1/2018	ADVERSE REACTIONS	DILAUDID INJECTION dosage Adjust the dosage to obtain a		
INDICATIONS AND USAGE DILAUDID INJECTION is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic	euphoria, dry mouth, and pruritus. (6)	2.6 Discontinuation of I		
and for which alternate treatments are inadequate. (1)	To report Suspected Adverse Reactions, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-	When a patient who has been		
Limitations of Use:	1088 or www.fda.gov/medwatch.	with DILAUDID INJECTION, ta		
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:	Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue DILAUDID INJECTION if serotonin	symptoms of withdrawal. If the either by increasing the interva		
Have not been tolerated, or are not expected to be tolerated	syndrome is suspected. (7)	DILAUDID INJECTION in a phy		
Have not provided adequate analgesia, or are not expected to provide adequate analgesia	• <u>Monoamine Oxidase Inhibitors (MAOIs)</u> : Can potentiate the effects of hydromorphone. Avoid concomitant use in patients	3 DOSAGE FORMS AN		
ODSAGE AND ADMINISTRATION     ODSAGE AND ADMINISTRATION     Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. Individualize	<ul> <li>receiving MAOIs or within 14 days of stopping treatment with an MAOI. (7)</li> <li><u>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</u>: Avoid use with DILAUDID INJECTION because they may</li> </ul>	DILAUDID INJECTION:		
dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse,	reduce analgesic effect of DILAUDID INJECTION or precipitate withdrawal symptoms. (7)	Each single-dose prefilled syr aqueous solution.		
and misuse. (2.1)  Initial Dosage:	USE IN SPECIFIC POPULATIONS	4 CONTRAINDICATION		
<ul> <li>Initial Dosage.</li> <li>Intramuscular or Subcutaneous Use: The usual starting dose is 1 mg to 2 mg every 2 to 3 hours as necessary. (2.2)</li> </ul>	Pregnancy: May cause fetal harm. (8.1)	DILAUDID INJECTION is contr		
- Intravenous Use: The usual starting dose is 0.2 mg to 1 mg every 2 to 3 hours. The injection should be given slowly, over at	See 17 for PATIENT COUNSELING INFORMATION.	• Significant respiratory de		
least 2 to 3 minutes. (2.2)	Revised: 10/2018	Acute or severe bronchia		
FULL PRESCRIBING INFORMATION: CONTENTS*	6 ADVERSE REACTIONS	Precautions (5.2)]		
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID	7 DRUG INTERACTIONS	Known or suspected gast		
WITHDRAWAL SYNDROME: and RISKS FROM CONCOMITANT USE WITH RENZODIAZEPINES OR OTHER CNS		Hyperconcitivity to hydr		
WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS	8 USE IN SPECIFIC POPULATIONS	<ul> <li>Hypersensitivity to hydro medications (e.g., anaphy</li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE	8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy			
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions	8 USE IN SPECIFIC POPULATIONS	medications (e.g., anaphy		
DEPRESSANTS  1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain		
DEPRESSANTS  1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION  2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 2.3 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Renal Impairment	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> </ul>	Medications (e.g., anaphy 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction		
DEPRESSANTS  1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 2.3 Dosage Modifications in Patients with Hepatic Impairment	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain		
DEPRESSANTS         1       INDICATIONS AND USAGE         2       DOSAGE AND ADMINISTRATION         2.1       Important Dosage and Administration Instructions         2.2       Initial Dosage         2.3       Dosage Modifications in Patients with Hepatic Impairment         2.4       Dosage Modifications in Patients with Renal Impairment         2.5       Titration and Maintenance of Therapy         2.6       Discontinuation of DILAUDID INJECTION         3       DOSAGE FORMS AND STRENGTHS	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PRI 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for o		
DEPRESSANTS         1         INDICATIONS AND USAGE         2       DOSAGE AND ADMINISTRATION         2.1       Important Dosage and Administration Instructions         2.2       Initial Dosage         2.3       Dosage Modifications in Patients with Hepatic Impairment         2.4       Dosage Modifications in Patients with Renal Impairment         2.5       Titration and Maintenance of Therapy         2.6       Discontinuation of DILAUDID INJECTION         3       DOSAGE FORMS AND STRENGTHS         4       CONTRAINDICATIONS	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PRI 5.1 Addiction, Abuse, an DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for a receiving DILAUDID INJECTIO		
DEPRESSANTS         1       INDICATIONS AND USAGE         2       DOSAGE AND ADMINISTRATION         2.1       Important Dosage and Administration Instructions         2.2       Initial Dosage         2.3       Dosage Modifications in Patients with Hepatic Impairment         2.4       Dosage Modifications in Patients with Renal Impairment         2.5       Titration and Maintenance of Therapy         2.6       Discontinuation of DILAUDID INJECTION         3       DOSAGE FORMS AND STRENGTHS	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PRI 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.6 Discontinuation of DILAUDID INJECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5 WARNINGS AND PRECAUTIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PR 5.1 Addiction, Abuse, an DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.6 Discontinuation of DILAUDID INJECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5 WARNINGS AND PRECAUTIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul>	5       WARNINGS AND PR         5       WARNINGS AND PR         5.1       Addiction, Abuse, and         DILAUDID INJECTION contain       users to the risks of addiction         Although the risk of addiction       Addiction can occur at recom         Assess each patient's risk for or       receiving DILAUDID INJECTIO         personal or family history of su       The potential for these risks sh         risk may be prescribed opioided       risks and proper use of DILAUDI		
<ul> <li>DEPRESSANTS</li> <li>1 INDICATIONS AND USAGE</li> <li>2 DOSAGE AND ADMINISTRATION <ul> <li>2.1 Important Dosage and Administration Instructions</li> <li>2.2 Initial Dosage</li> <li>2.3 Dosage Modifications in Patients with Hepatic Impairment</li> <li>2.4 Dosage Modifications in Patients with Renal Impairment</li> <li>2.5 Titration and Maintenance of Therapy</li> <li>2.6 Discontinuation of DILAUDID INJECTION</li> </ul> </li> <li>3 DOSAGE FORMS AND STRENGTHS <ul> <li>4 CONTRAINDICATIONS</li> <li>5.1 Addiction, Abuse, and Misuse</li> <li>5.2 Life-Threatening Respiratory Depression</li> <li>5.3 Neonatal Opioid Withdrawal Syndrome</li> <li>5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or</li> </ul> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> </ul>	medications (e.g., anaphy 5 WARNINGS AND PR 5.1 Addiction, Abuse, an DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids		
<ul> <li>DEPRESSANTS</li> <li>1 INDICATIONS AND USAGE</li> <li>2 DOSAGE AND ADMINISTRATION <ul> <li>1 Important Dosage and Administration Instructions</li> <li>2 Initial Dosage</li> <li>3 Dosage Modifications in Patients with Hepatic Impairment</li> <li>4 Dosage Modifications in Patients with Renal Impairment</li> <li>5 Titration and Maintenance of Therapy</li> <li>6 Discontinuation of DILAUDID INJECTION</li> </ul> </li> <li>3 DOSAGE FORMS AND STRENGTHS <ul> <li>4 CONTRAINDICATIONS</li> <li>5.1 Addiction, Abuse, and Misuse</li> <li>5.2 Life-Threatening Respiratory Depression</li> <li>5.3 Neonatal Opioid Withdrawal Syndrome</li> <li>5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>5.6 Adrenal Insufficiency</li> </ul> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> </ul> </li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>5 WARNINGS AND PR</li> <li>5.1 Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction</li> <li>Although the risk of addiction</li> <li>Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO</li> <li>personal or family history of su</li> <li>The potential for these risks sh</li> <li>risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispensina appropriate quantity. Contact</li> </ul>		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Dosage Modifications in Patients with Renal Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ul> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>Subscience of Merapy Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adviency S, Severe Hypotension</li> </ul> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Adthough the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Dosage Modifications in Patients with Renal Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ul> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>SUMARNINGS AND PRECAUTIONS</li> <li>Life-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adreal Insufficiency</li> <li>Source Hypotension</li> <li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> </ul> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Adthough the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispension appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening Re		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION <ol> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Dosage Modifications in Patients with Renal Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>3 DOSAGE FORMS AND STRENGTHS <ol> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>Addiction, Abuse, and Misuse</li> <li>Life-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>Kiks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adrenal Insufficiency</li> <li>Yevere Hypotension</li> <li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> </ol> </li> </ol></li></ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> </ul> </li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening Re Serious, life-threatening, or recommended. Respiratory d		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Dosage Modifications in Patients with Renal Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ul> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>S.1 Addiction, Abuse, and Misuse</li> <li>Life-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>A Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Sief Artenating Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adrana Insufficiency</li> <li>Severe Hypotension</li> <li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> <li>S.11 Withdrawal</li> <li>S.12 Risks of Driving and Operating Machinery</li> </ul> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening Re Serious, life-threatening, or recommended. Respiratory of Management of respiratory of		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Dosage Modifications in Patients with Renal Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Titration and Maintenance of Therapy</li> <li>DosaGE FORMS AND STRENGTHS</li> </ol> </li> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS <ol> <li>Ideation, Abuse, and Misuse</li> <li>Ife-Threatening Respiratory Depression</li> <li>A Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Sief-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adrenal Insufficiency</li> <li>Severe Hypotension</li> <li>Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> <li>Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Withdrawal</li> </ol> </li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> </ul> </li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispension appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening Re Serious, life-threatening, or recommended. Respiratory of Management of respiratory of depending on the patient's cli		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION <ol> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ol> <li>CONTRAINDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>Standation, Abuse, and Misuse</li> <li>Life-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>Kisks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Adrenal Insufficiency</li> <li>Ser Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> <li>Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Withdrawal</li> <li>Risks of Diving and Operating Machinery</li> <li>Sulfites</li> <li>Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration</li> </ol> </li> </ol></li></ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> </ul> </li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening Re Serious, life-threatening, or recommended. Respiratory of Management of respiratory of depending on the patient's cli depression can exacerbate th While serious, life-threatening		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Important Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ul> <li>CONTRAINDICATIONS</li> </ul> </li> <li>WARNINGS AND PRECAUTIONS <ul> <li>Iddiction, Abuse, and Misuse</li> <li>Life-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>Kirsk form Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>Si Iddiction, Abuse, and Misuse</li> <li>Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Addrenal Insufficiency</li> <li>Si Reiks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> <li>In Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Risks of Dise in Patients with Gastrointestinal Conditions</li> <li>In Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Si Risks of Dise in Patients with Seizure Disorders</li> <li>Si In Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Si In Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration</li> </ul> </li> <li>FULL PRESCRIBING INFORMATION</li> </ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Impairment of Fertility</li> </ul> </li> <li>16 HOW SUPPLIE/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul>	5 WARNINGS AND PR 5 WARNINGS AND PR 5.1 Addiction, Abuse, ar DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab 5.2 Life-Threatening, or recommended. Respiratory of Management of respiratory of depending on the patient's cli depression can exacerbate th While serious, life-threatening, risk is greatest during the initi		
<ul> <li>DEPRESSANTS         <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION                 <ol></ol></li></ol></li></ul>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> </ul> </li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>5.2 Life-Threatening Re</li> <li>Serious, life-threatening, or recommended. Respiratory of Management of respiratory of depending on the patient's clid depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initit especially within the first 24-</li> </ul>		
<ul> <li>DEPRESSANTS <ol> <li>INDICATIONS AND USAGE</li> <li>DOSAGE AND ADMINISTRATION</li> <li>Imital Dosage and Administration Instructions</li> <li>Initial Dosage</li> <li>Dosage Modifications in Patients with Hepatic Impairment</li> <li>Titration and Maintenance of Therapy</li> <li>Discontinuation of DILAUDID INJECTION</li> </ol> </li> <li>DOSAGE FORMS AND STRENGTHS <ul> <li>CONTRAINDICATIONS</li> </ul> </li> <li>WARNINGS AND PRECAUTIONS</li> <li>MADIAUDICATIONS</li> <li>WARNINGS AND PRECAUTIONS</li> <li>Itife-Threatening Respiratory Depression</li> <li>Neonatal Opioid Withdrawal Syndrome</li> <li>A Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</li> <li>S.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</li> <li>Se Adrenal Insufficiency</li> <li>Se Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</li> <li>Risks of Use in Patients with Gastrointestinal Conditions</li> <li>In Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Sith Increased Risk of Seizures in Patients with Seizure Disorders</li> <li>Sith Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration</li> </ul> <li>FULL PRESCRIBING INFORMATION</li>	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> </ul> </li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION <ul> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE</li> <li>DILAUDID INJECTION SI Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction</li> <li>Although the risk of addiction</li> <li>Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO</li> <li>personal or family history of su</li> <li>The potential for these risks sh</li> <li>risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispensin appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li>5.2 Life-Threatening, or</li> <li>recommended. Respiratory d</li> <li>Management of respiratory d</li> <li>depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initi especially within the first 24- To reduce the risk of respirat</li> <li>Administration (2)]. Overestin</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.6 Discontinuation of DILAUDI INJECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants         5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7 Severe Hypotension         5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness         5.9 Risks of Use in Patients with Seizure Disorders         5.1.1 Withdrawal         5.1.2 Risks of Diving and Operating Machinery         5.1.3 Sulfites         5.1.4 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration         FULL PRESCRIBING INFORMATION         WARNIN	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE <ul> <li>DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of alternative treatment options [sequence Discussions on alternative treatment options [sequence Discussions on the precautions of CJ)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [seq Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of the risks of addiction on the use in patients for whom alternative treatment options [sequence Discussions]</li> </ul></li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24-1</li> <li>To reduce the risk of respirat <i>Administration (2)</i>. Overestin result in a fatal overdose with</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.6 Discontinuation of DILAUDID INJECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5 Utife-Threatening Respiratory Depression         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7 Severe Hypotension         5.8 Risks of Use in Patients with Gastrointestinal Conditions         5.10 Increased Risk of Seizures in Patients with Seizure Disorders         5.11 Writhdrawal         5.12 Risks of Diving and Operating Machinery         5.13 Sulfites         5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration         FULL PRESCRIBING INFORMATION         Withdrawal         Suffice         State of Diving and Operating Machinery         5.13 Sulfites       State of Se	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE <ul> <li>DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.11), reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</li> </ul></li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>5.1 Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Adthough the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispension appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li>5.2 Life-Threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate the While serious, life-threatening, risk is greatest during the initit especially within the first 24- To reduce the risk of respirata</li> <li>Administration (2)]. Overestin result in a fatal overdose with</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.5 Discontinuation of DILAUDID INJECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants         5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7 Severe Hypotension         5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness         5.9 Risks of Use in Patients with Gastrointestinal Conditions         5.10 Increased Risk of Seizures in Patients with Seizure Disorders         5.11 Withdrawal         5.12 Risks of Driving and Operating Machinery         5.13 Sulfites         5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ul> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ul> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE <ul> <li>DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of alternative treatment options [sequence Discussions on alternative treatment options [sequence Discussions on the precautions of CJ)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [seq Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [sequence Discussions of the risks of addiction on the use in patients for whom alternative treatment options [sequence Discussions]</li> </ul></li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>5.1 Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUII</li> <li>Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>5.2 Life-Threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initi especially within the first 24- To reduce the risk of respirat <i>Administration (2)</i>. Overestin result in a fatal overdose with</li> <li>5.3 Neonatal Opioid With Syndrome, unlike opioid with</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications in Patients with Renal Impairment         2.5 Titration and Maintenance of Therapy         2.6 Discontinuation of DILAUDID INIECTION         3 DOSAGE FORMS AND STRENGTHS         4 CONTRAINDICATIONS         5 WARNINGS AND PRECAUTIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Adisks from Concomitant Use with Benzodiazepines or Other CNS Depressants         5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7. Severe Hypotension         5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness         5.9 Risks of Dise in Patients with Gastrointestinal Conditions         5.10 Increased Risk of Seizures in Patients with Seizure Disorders         5.11 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration         FULL PRESCRIBING INFORMATION <td <="" colspan="2" td=""><td><ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>11 NDICATIONS AND USAGE DILAUDID INJECTION Is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <i>[see Warnings and Precautions (S.I)]</i>, reserve DILAUDID INJECTION INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: <ul> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> </ul></li></ul></td><td><ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispension appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24</li> <li>To reduce the risk of respirata <i>Administration (2)]</i>. Overestin result in a fatal overdose with</li> <li><b>5.3 Neonatal Opioid Wir</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p</li> </ul></td></td>	<td><ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>11 NDICATIONS AND USAGE DILAUDID INJECTION Is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <i>[see Warnings and Precautions (S.I)]</i>, reserve DILAUDID INJECTION INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: <ul> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> </ul></li></ul></td> <td><ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispension appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24</li> <li>To reduce the risk of respirata <i>Administration (2)]</i>. Overestin result in a fatal overdose with</li> <li><b>5.3 Neonatal Opioid Wir</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p</li> </ul></td>		<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>11 NDICATIONS AND USAGE DILAUDID INJECTION Is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <i>[see Warnings and Precautions (S.I)]</i>, reserve DILAUDID INJECTION INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: <ul> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> </ul></li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispension appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24</li> <li>To reduce the risk of respirata <i>Administration (2)]</i>. Overestin result in a fatal overdose with</li> <li><b>5.3 Neonatal Opioid Wir</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p</li> </ul>
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 3.2 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Renal Impairment 2.5 Titration and Maintenance of Therapy 2.6 Discontinuation of DILAUDDI INJECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression 5.3 Neonatal Opioid Withdrawal Syndrome 5.4 Risks for Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.6 Adrenal Insufficiency 5.7 Severe Hypotension 5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness 5.9 Risks of Use in Patients with Conditions 5.10 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks for Driving and Operating Machinery 5.13 Suffies 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIODD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse DILAUDID INJECTION Asposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing DILAUDID INJECTION and monitor all patients regulary for the development of these behaviors and conditions <i>See Warnings and Precautions (S. 1)</i> , Life-Threatening, or fatal respiratory depression may occur with use of DILAUDID INJECTION. Monitor	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ol> <li>Pregnancy</li> <li>2. Lactation</li> <li>Pregnancy</li> <li>2. Lactation</li> <li>3. Females and Males of Reproductive Potential</li> <li>4. Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> </ol> </li> <li>9 DRUG ABUSE AND DEPENDENCE <ol> <li>1. Controlled Substance</li> <li>2. Abuse</li> <li>3.3 Dependence</li> </ol> </li> <li>10 OVERDOSAGE <ol> <li>DESCRIPTION</li> </ol> </li> <li>12 CLINICAL PHARMACOLOGY <ol> <li>1.1 DESCRIPTION</li> <li>2.2 Pharmacodynamics</li> <li>1.2.3 Pharmacokinetics</li> </ol> </li> <li>13 NONCLINICAL TOXICOLOGY <ol> <li>1.3.1 Carcinogenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>7 PATIENT COUNSELING INFORMATION </li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ol> </li> <li>1 INDICATIONS AND USAGE DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <i>[see Warnings and Precautions (S.I.)</i>, reserve DILAUDID INJECTION INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: <ol> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> </ol> </li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids</li> <li>risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab</li> <li>when prescribing or dispension appropriate quantity. Contact</li> <li>how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24- To reduce the risk of respirat <i>Administration (2)].</i> Overestin result in a fatal overdose with</li> <li><b>5.3 Neonatal Opioid Wir</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications of DILAUDID INECTION         3 DOSAGE FORMS AND STREMOTHS         4 CONTRAINDICATIONS         5 UKANINICS AND PRECAUTIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants         5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7 Severe Hypotension         5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness         5.9 Risks of Use in Patients with Seizure Disorders         5.11 Withdrawal         5.12 Suffites         5.13 Sulfites         5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration         Summary Sumery Summary Summary Sumary Summary Summary Summary Summary Summary	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY <ul> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacokinetics</li> </ul> </li> <li>13 NONCLINICAL TOXICOLOGY <ul> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>11 NDICATIONS AND USAGE DILAUDID INJECTION Is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <i>[see Warnings and Precautions (S.I)]</i>, reserve DILAUDID INJECTION INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: <ul> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> </ul></li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUD</li> <li>Opioids are sought by drug ab when prescribing or dispension appropriate quantity. Contact how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening risk is greatest during the initi especially within the first 24- To reduce the risk of respirat Administration (2)]. Overestin result in a fatal overdose with</li> <li><b>5.3 Neonatal Opioid Wi</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p withdrawal syndrome and m neonatal opioid withdrawal s</li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 4 Administration Instructions 2.2 Initial Dosage 4 Administration Instructions 2.3 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Henal Impairment 2.5 Discontinuation of DILAUDID INJECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression 5.3 Neonatal Opioid Withdrawal Syndrome 5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.6 Adreal Insufficieny 5.7 Severe Hypotension 5.8 Risks of Use in Patients with Gastrointestimal Conditions 5.10 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Dirving and Operating Machinery 5.13 Suffites 5.14 Increased Risk of Seizures in Patients with Seizure Disorders 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction. Abuse, and Misuse DILAUDID INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing DILAUDID INJECTION and monitor all patients regularly for the development of these behaviors and conditions <i>[see Warnings and Precautions [5.1]</i> . Neonatal Opioid Withdrawal Syndrome	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>13 NONCLINICAL TOXICOLOGY</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> <li>1 INDICATIONS AND USAGE</li> <li>DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Lise:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions [5.1]], reserve DILAUDID INJECTION for use in patients for whom alternative treatment apoing inalgesics or opioid combination products]:</li> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> <li>4.1 Important Dosage and Administration Instructions</li> <li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (S)].</li> <li>Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient</li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for of receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab when prescribing or dispension appropriate quantity. Contact how to prevent and detect ab</li> <li>Life-Threatening Re</li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate the While serious, life-threatening risk is greatest during the initii especially within the first 24 To reduce the risk of respirat Administration (2)]. Overestin result in a fatal overdose with</li> <li>S.3 Neonatal Opioid With management according to p withdrawal syndrome and m neonatal opioid withdrawal s (8.1), Patient Counseling Info</li> <li>Risks from Concomi</li> </ul>		
DEPRESSANTS         1 INDICATIONS AND USAGE         2 DOSAGE AND ADMINISTRATION         2.1 Important Dosage and Administration Instructions         2.2 Initial Dosage         2.3 Dosage Modifications in Patients with Hepatic Impairment         2.4 Dosage Modifications of DILAUDID INECTION         3 DOSAGE FORMS AND STREMOTHS         4 CONTRAINDICATIONS         5 UKANINICS AND PRECAUTIONS         5.1 Addiction, Abuse, and Misuse         5.2 Life-Threatening Respiratory Depression         5.3 Neonatal Opioid Withdrawal Syndrome         5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants         5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients         5.6 Adrenal Insufficiency         5.7 Severe Hypotension         5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness         5.9 Risks of Use in Patients with Seizure Disorders         5.11 Withdrawal         5.12 Suffites         5.13 Sulfites         5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration         Summary Sumery Summary Summary Sumary Summary Summary Summary Summary Summary	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> <li>13 NONCLINICAL TOXICOLOGY</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> <li>1 INDICATIONS AND USAGE</li> <li>DIALDUID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</li> <li>Have not been tolerated, or are not expected to be tolerated</li> <li>Have not been tolerated, or are not expected to be rowide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> <li>2.1 Important Dosage and Administration Instructions</li> <li>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions fol].</li> </ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>1 Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Although the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>Life-Threatening, or recommended. Respiratory of Management of respiratory of depending on the patient's cli depression can exacerbate the While serious, life-threatening, risk is greatest during the initie especially within the first 24- To reduce the risk of respiratory administration (2)]. Overestin result in a fatal overdose with 5.3 Neonatal Opioid With Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p withdrawal syndrome and m neonatal opioid withdrawal s (8.1), Patient Counseling Info 5.4 Risks from Concomi</li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 3.3 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Renal Impairment 2.5 Discontinuation of DILAUDID INJECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 UVARNINGS AND PRECAUTIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.6 Adrenal Insufficiency 5.7 Severe Hypotension 5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness 5.9 Risks of Use in Patients with Gastrointestinal Conditions 5.10 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Driving and Operating Machinery 5.13 Suffites 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse DILAUDID INJECTION aestients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to everdose and Heath, Assesse each patient's risk prior to prescribing DILAUDID INJECTION. Monitor all patients regularly for the development of these behaviors and conditions (5:1)]. Life-Threatening Respiratory Depression Series, Iffe-threatening (5:2)]. Meonatal Opioid Withdrawal Syndrome Prolonged use of DILAUDID INJECTION Monitor	<ul> <li>8 USE IN SPECIFIC POPULATIONS</li> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8.7 Renal Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacodynamics</li> <li>12.3 Pharmacokinetics</li> <li>13 NONCLINICAL TOXICOLOGY</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIE/STORAGE AND HANDLING</li> <li>17 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> <li>1 INDICATIONS AND USAGE</li> <li>DIAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.</li> <li>Limitations of Use:</li> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve DIAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</li> <li>A Have not been tolerated, or are not expected to be tolerated</li> <li>Have not been tolerated, or are not expected to provide adequate analgesia</li> <li>2 DOSAGE AND ADMINISTRATION</li> <li>Sue the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5.1)].</li> <li>Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment sepreince, and risk factors for addiction, abuse, and misuse (see Warnings and Precautions (5.1)).</li> <li>Initiate the dosing regimen for each patient individually, taking into account</li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>1 Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Adthough the risk of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for or receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioid risks and proper use of DILAUD</li> <li>Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li><b>5.2 Life-Threatening Re</b></li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate the While serious, life-threatening risk is greatest during the initi especially within the first 24- To reduce the risk of respirat <i>Administration (2)</i>. Overestin result in a fatal overdose witt</li> <li><b>5.3 Neonatal Opioid Wir</b></li> <li>Prolonged use of DILAUDID II syndrome, unlike opioid with management according to p withdrawal syndrome and m neonatal opioid withdrawal s <i>(8.1), Patient Counseling Info</i></li> <li><b>5.4 Risks from Concomi</b></li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 3.3 Dosage Modifications in Patients with Hepatic Impairment 3.4 Dosage Modifications in Patients with Renal Impairment 3.5 Tirtation and Maintenance of Therapy 3.6 Discontinuation of DILAUDID INJECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression 5.3 Neonatal Opioid Withdrawal Syndrome 5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.6 Adrenal Insufficiency 5.7 Severe Hypotension 5.8 Risks of Use in Patients with Gastrointestinal Conditions 5.9 Risks of Use in Patients with Gastrointestinal Conditions 5.11 Withdrawal 5.12 Risks of Driving and Operating Machinery 5.13 Suffits 5.14 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse DILAUDID INJECTION Resposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescripting DILAUDID INJECTION and monitor all patients regularly for the development of these behaviors and conditions [ <i>see Warnings and Precautions (5.1)</i> ]. Life-Threatening Respiratory Depression Serious, life-threatening if not recognized and recur with use of DILAUDID INJECTION. Monitor for respiratory depression Serious billet-threatening if not recognized and recur and and requires management according to protocols	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacolynamics <ul> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> </ul> </li> <li>17 PATIENT COUNSELING INFORMATION <ul> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Recause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions [5,1]], reserve DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Recause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions [5,1]], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</li> <li>Have not provided adequate analgesia, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia or opioid combination products]:</li> <li>Have not provided adequate analgesia, or are not</li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab</li> <li>when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>Life-Threatening Re</li> <li>Serious, life-threatening, or recommended. Respiratory d</li> <li>Management of respiratory d</li> <li>depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initii especially within the first 24-3</li> <li>To reduce the risk of respiratory di depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initii especially within the first 24-3</li> <li>To reduce the risk of respiratory of syndrome, unlike opioid with management according to p</li> <li>withdrawal syndrome and m neonatal opioid withdrawal s (<i>8.1</i>), Patient Counseling Info</li> <li>Risks from Concomi</li> <li>Profound sedation, respiratory benzodiazepines or other CU relaxants, general anesthetics these drugs for use in patient</li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Instructions 2.2 Initial Dosage 3.3 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Hepatic Impairment 2.5 Titration and Maintenance of Therapy 2.6 Discontinuation of DIAUDID INJECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression 5.3 Neonatal Opioid Withdrawal Syndrome 5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly. Cachectic, or Debilitated Patients 5.4 Risks form Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly. Cachectic, or Debilitated Patients 5.6 Adrenal Insufficiency 5.7 Sever Hypotension 5.8 Risks of Use in Patients with Gastrointestinal Conditions 5.10 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Use in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Sites 5.14 Increased Risk of Seizures in Patients with Seizure Disorders 5.13 Withdrawal 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse DILAUDID INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing DILAUDID INJECTION. Annotor for respiratory Depression Serious, life-threatening Respiratory Depression Serious, life-threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression ma	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>8 PRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> <li>10 OVERDOSAGE</li> <li>11 DESCRIPTION</li> </ul> </li> <li>12 Pharmacodynamics <ul> <li>12.3 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>12.3 Pharmacodynamics</li> <li>13 NONCLINICAL TOXICOLOGY</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> <li>7 PATIENT COUNSELING INFORMATION</li> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>11 INDICATIONS AND USAGE DILAUDID INJECTION for use in patients of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: Recause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combinistration instructions Lose the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment goals [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combinistration Instructions Lose the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5.1)], reserve DILAUDID INJECTION for use in patients for whom alternative treatment goals [see Warnings and Precaut</li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, an</li> <li>DILAUDID INJECTION contain users to the risks of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI</li> <li>Opioids are sought by drug ab when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>Life-Threatening Re</li> <li>Serious, life-threatening, or recommended. Respiratory of depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening, is is greatest during the initi especially within the first 24-3 To reduce the risk of respiratory of <i>S.3 Neonatal Opioid With</i> <i>Prolonged use of DILAUDI II</i> syndrome, unlike opioid with management according to p withdrawal syndrome and m neonatal opioid withdrawal s (<i>8.1</i>), <i>Patient Counseling Info</i></li> <li><i>S.4 Risks from Concomi</i></li> <li>Profound sedation, respirator benzodiazepines or other CI relaxants, general anesthetics these drugs for use in patient</li> </ul>		
DEPRESSANTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration instructions 2.2 Initial Dosage 3.3 Dosage Modifications in Patients with Hepatic Impairment 2.4 Dosage Modifications in Patients with Hepatic Impairment 2.5 Titration and Maintenance of Therapy 2.6 Discontinuation of DILAUDID INVECTION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 VARNINGS AND PRECAUTIONS 5.1 Addiction, Abuse, and Misuse 5.2 Life-Threatening Respiratory Depression 5.3 Nonatal Opioid Withdrawal Syndrome 5.4 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients 5.6 Adrenal Insufficiency 5.7 Severe Hypotension 5.8 Risks of Use in Patients with Gastrointestinal Conditions 5.10 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Use in Patients with Gastrointestinal Conditions 5.11 Oncreased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Use in Patients with Gastrointestinal Conditions 5.11 Increased Risk of Seizures in Patients with Seizure Disorders 5.11 Withdrawal 5.12 Risks of Dytoing and Operating Machinery 5.13 Suffites 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration FULL PRESCRIBING INFORMATION WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse DILAUDID INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each opatient's risk prior to prescribing DILAUDID INJECTION. Monitor for respiratory Depression may occur with use of DILAUDID INJECTION. Monitor for respiratory depression especially during initiation of DILAUDID INJECTION. Monitor for respiratory d	<ul> <li>8 USE IN SPECIFIC POPULATIONS <ul> <li>8.1 Pregnancy</li> <li>8.2 Lactation</li> <li>8.3 Females and Males of Reproductive Potential</li> <li>8.4 Pediatric Use</li> <li>8.5 Geriatric Use</li> <li>8.5 Geriatric Use</li> <li>8.6 Hepatic Impairment</li> <li>9 DRUG ABUSE AND DEPENDENCE</li> <li>9.1 Controlled Substance</li> <li>9.2 Abuse</li> <li>9.3 Dependence</li> </ul> </li> <li>10 OVERDOSAGE <ul> <li>11 DESCRIPTION</li> </ul> </li> <li>12 CLINICAL PHARMACOLOGY</li> <li>12.1 Mechanism of Action</li> <li>12.2 Pharmacolynamics <ul> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>12.3 Pharmacolynamics</li> <li>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</li> <li>16 HOW SUPPLIED/STORAGE AND HANDLING</li> </ul> </li> <li>17 PATIENT COUNSELING INFORMATION <ul> <li>*Sections or subsections omitted from the full prescribing information are not listed.</li> </ul> </li> <li>1 INDICATIONS AND USAGE DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Recause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions [5,1]], reserve DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Recause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions [5,1]], reserve DILAUDID INJECTION for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</li> <li>Have not provided adequate analgesia, or are not expected to be tolerated</li> <li>Have not provided adequate analgesia, or are not expected to provide adequate analgesia or opioid combination products]:</li> <li>Have not provided adequate analgesia, or are not</li></ul>	<ul> <li>medications (e.g., anaphy</li> <li>WARNINGS AND PR</li> <li>Addiction, Abuse, ar</li> <li>DILAUDID INJECTION contain users to the risks of addiction Addiction can occur at recom</li> <li>Assess each patient's risk for a receiving DILAUDID INJECTIO personal or family history of su</li> <li>The potential for these risks sh risk may be prescribed opioids risks and proper use of DILAUI Opioids are sought by drug ab</li> <li>when prescribing or dispensin appropriate quantity. Contact how to prevent and detect ab</li> <li>Life-Threatening Re</li> <li>Serious, life-threatening, or recommended. Respiratory d</li> <li>Management of respiratory d</li> <li>depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initii especially within the first 24-3</li> <li>To reduce the risk of respiratory di depending on the patient's cli depression can exacerbate th</li> <li>While serious, life-threatening, risk is greatest during the initii especially within the first 24-3</li> <li>To reduce the risk of respiratory of syndrome, unlike opioid with management according to p</li> <li>withdrawal syndrome and m neonatal opioid withdrawal s (<i>8.1</i>), Patient Counseling Info</li> <li>Risks from Concomi</li> <li>Profound sedation, respiratory benzodiazepines or other CU relaxants, general anesthetics these drugs for use in patient</li> </ul>		

- Reserve concomitant prescribing of DILAUDID Injection and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.

• Follow patients for signs and symptoms of respiratory depression and sedation.

The usual starting dose of DILAUDID INJECTION is 1 mg to 2 mg every 2 to 3 hours as necessary. Depending on the clinical situation, the initial starting dose may be lowered in patients who are opioid naïve.

2.2 Initial Dosage

Use of DILAUDID INJECTION as the First Opioid Analgesic:

Subcutaneous or Intramuscular Administration.

e demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of site reactions, peripheral edema pared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable Hepatobiliary disorders: biliary colic the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7)]. Immune system disorders: anaphylactic reactions, hypersensitivity reactions If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe Investigations: hepatic enzymes increased the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, Metabolism and nutrition disorders: decreased appetite prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and Musculoskeletal and connective tissue disorders: muscle rigidity titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS Nervous system disorders: headache, tremor, paraesthesia, nystagmus, increased intracranial pressure, syncope, taste depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely alteration, involuntary muscle contractions, presyncope, convulsion, drowsiness, dyskinesia, hyperalgesia, lethargy, for signs and symptoms of respiratory depression and sedation. myoclonus, somnolence

5 0.2 to 1 mg every 2 to 3 hours. Intravenous administration should be given slowly, over at least 2 to 3 e dose. The initial dose should be reduced in the elderly or debilitated and may be lowered to 0.2 mg. ioids to DILAUDID INJECTION

iability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach age than to overestimate the 24-hour DILAUDID INJECTION dosage and manage an adverse reaction or Debilitated Patients

convert to Hydromorphone Hydrochloride Injection from another opioid analgesic using publicly e current total daily amount(s) of opioid(s) received to an equivalent total daily dose of DILAUDID one-half due to the possibility of incomplete cross tolerance. Divide the new total amount by the based on dosing interval (e.g., 8 doses for every-three-hour dosing). Titrate the dose according to

#### tions in Patients with Hepatic Impairment

mpairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the Clinical Pharmacology (12.3)].

#### tions in Patients with Renal Impairment

npairment on one-fourth to one-half the usual DILAUDID INJECTION starting dose depending on the e Clinical Pharmacology (12.3)]

#### intenance of Therapy

ID INJECTION to a dose that provides adequate analgesia and minimizes adverse reactions. Continually ving DILAUDID INJECTION to assess the maintenance of pain control and the relative incidence of as monitoring for the development of addiction, abuse, or misuse [see Warnings and Precautions cation is important among the prescriber, other members of the healthcare team, the patient, and the eriods of changing analgesic requirements, including initial titration.

ases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID INJECTION may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There sage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. in an appropriate balance between management of pain and opioid-related adverse reactions.

# of DILAUDID INJECTION

been taking DILAUDID INJECTION regularly and may be physically dependent no longer requires therapy , taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and f the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, erval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue physically-dependent patient [see Warnings and Precautions (5.11), Drug Abuse and Dependence (9.3)]. AND STRENGTHS

syringe contains 0.5 mg/0.5 mL, 1 mg/mL or 2 mg/mL of hydromorphone hydrochloride in a sterile,

ontraindicated in patients with:

depression [see Warnings and Precautions (5.2)]

chial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and

# gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.9)]

dromorphone, hydromorphone salts, any other components of the product, or sulfite containing phylaxis) [see Warnings and Precautions (5.13)]

# PRECAUTIONS

#### and Misuse

tains hydromorphone, a Schedule II controlled substance. As an opioid, DILAUDID INJECTION exposes tion, abuse, and misuse [see Drug Abuse and Dependence (9)].

tion in any individual is unknown, it can occur in patients appropriately prescribed DILAUDID INJECTION. ommended dosages and if the drug is misused or abused.

or opioid addiction, abuse, or misuse prior to prescribing DILAUDID INJECTION and monitor all patients substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). should not, however, prevent the proper management of pain in any given patient. Patients at increased DILAUDID INJECTION contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic ioids such as DILAUDID INJECTION but use in such patients necessitates intensive counseling about the AUDID INJECTION along with intensive monitoring for signs of addiction, abuse, and misuse.

abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks nsing DILAUDID INJECTION. Strategies to reduce these risks include prescribing the drug in the smallest tact local state professional licensing board or state controlled substances authority for information on abuse or diversion of this product.

#### **Respiratory Depression**

or fatal respiratory depression has been reported with the use of opioids, even when used as depression, if not immediately recognized and treated, may lead to respiratory arrest and death. y depression may include close observation, supportive measures, and use of opioid antagonists, clinical status [see Overdosage (10)]. Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory the sedating effects of opioids.

ning, or fatal respiratory depression can occur at any time during the use of DILAUDID INJECTION, the nitiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, 24-72 hours of initiating therapy with and following dosage increases of DILAUDID INJECTION.

ratory depression, proper dosing and titration of DILAUDID INJECTION is essential *(see Dosage and* estimating the DILAUDID INJECTION dosage when converting patients from another opioid product can • Seizures [see Warnings and Precautions (5.10)] with the first dose

### Withdrawal Syndrome

vithdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of The most common adverse effects are lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, Information (17)].

### omitant Use with Benzodiazepines or Other CNS Depressants

atory depression, coma, and death may result from the concomitant use of DILAUDID Injection with Cardiac disorders: tachycardia, bradycardia, palpitations CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle Eye disorders: vision blurred, diplopia, miosis, visual impairment etics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of *Gastrointestinal disorders*: constipation, ileus, diarrhea, abdominal pain ients for whom alternative treatment options are inadequate.

benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions (7) and Patient Counseling Information (17)].

ning the total daily dosage of DILAUDID INJECTION. It is safer to underestimate a patient's 24-hour 5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic,

### The use of DILAUDID INJECTION in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated

Patients with Chronic Pulmonary Disease: DILAUDID INJECTION treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercaphia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of DILAUDID INJECTION [see Warnings and Precautions (5.2)]

Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see Warnings and Precautions (5.2)]

Monitor such patients closely, particularly when initiating and titrating DILAUDID INJECTION and when DILAUDID INJECTION is given concomitantly with other drugs that depress respiration [see Warnings and Precautions (5.2)]. Alternatively, consider the use of non-opioid analgesics in these patients

#### 5.6 Adrenal Insufficiency

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

### 5.7 Severe Hypotension

is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see Drug Interactions (7)]. Monitor these patients for signs of hypotension after initiating or titrating the dosage of DILAUDID INJECTION. In patients with circulatory shock, DILAUDID INJECTION may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of DILAUDID INJECTION in patients with circulatory shock.

### 5.8 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousnes

In patients who may be susceptible to the intracranial effects of CO, retention (e.g., those with evidence of increased intracranial pressure or brain tumors). DILAUDID INJECTION may reduce respiratory drive, and the resultant CO, retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with DILAUDID INJECTION

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of DILAUDID INJECTION in patients with impaired consciousness or coma

## 5.9 Risks of Use in Patients with Gastrointestinal Conditions

DILAUDID INJECTION is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus. The hydromorphone in DILAUDID INJECTION may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

# 5.10 Increased Risk of Seizures in Patients with Seizure Disorders

The hydromorphone in DILAUDID INJECTION may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during DILAUDID INJECTION therapy.

### 5.11 Withdrawa

Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including DILAUDID INJECTION. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms [see Drug Interactions (7)].

When discontinuing DILAUDID INJECTION in a physically-dependent patient, gradually taper the dosage [see Dosage and Administration (2.6)]. Do not abruptly discontinue DILAUDID INJECTION in these patients [see Drug Abuse and Dependence (9.3)]. 5.12 Risks of Driving and Operating Machiner

DILAUDID INJECTION may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to TION for the development of these behaviors and conditions. Risks are increased in patients with a the effects of DILAUDID INJECTION and know how they will react to the medication [see Patient Counseling Information (17)]. 5.13 Sulfite

symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

#### 5.14 Increased Risk of Hypotension and Respiratory Depression with Rapid Intravenous Administration

DILAUDID INJECTION may be given intravenously, but the injection should be given very slowly. Rapid intravenous injection of opioid analgesics increases the possibility of side effects such as hypotension and respiratory depression [see Dosage and Administration (2)].

### ADVERSE REACTIONS

The following serious adverse reactions are described, or described in greater detail, in other sections:

- Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1)]
- Life-Threatening Respiratory Depression (see Warnings and Precautions (5.2))
- Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.3)]
- Interactions with Benzodiazepines and Other CNS Depressants [see Warnings and Precautions (5.4)
- Adrenal Insufficiency [see Warnings and Precautions (5.6)]
- Severe Hypotension [see Warnings and Precautions (5.7)]
- Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.9)]
- Withdrawal [see Warnings and Precautions (5.11)]

The following adverse reactions associated with the use of hydromorphone were identified in clinical studies or postmarketin reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible D INJECTION during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serious adverse reactions associated with DILAUDID INJECTION include respiratory depression and apnea and, to a lesser degree. circulatory depression, respiratory arrest, shock, and cardiac arrest.

al syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations euphoria, dry mouth, and pruritus. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain.

# Less Frequently Observed Adverse Reactions

General disorders and administration site conditions; weakness, feeling abnormal, chills, injection site urticaria, fatigue, injection

Advise both patients and caregivers about the risks of respiratory depression and sedation when DILAUDID Injection is used with Psychiatric disorders: agitation, mood altered, nervousness, anxiety, depression, hallucination, disorientation, insomnia, abnormal dreams

Renal and urinary disorders: urinary retention, urinary hesitation, antidiuretic effects Reproductive system and breast disorders: erectile dysfunction Respiratory, thoracic, and mediastinal disorders: bronchospasm, laryngospasm, dyspnea, oropharyngeal swelling Skin and subcutaneous tissue disorders: injection site pain, urticaria, rash, hyperhidrosis

Vascular disorders: flushing, hypotension, hypertension

use of opioids with serotonergic drugs.

Anaphylaxis: Anaphylaxis has been reported with ingredients contained in DILAUDID INJECTION. Androgen deficiency: Cases of androgen deficiency have occurred with chronic use of opioids [see Clinical Pharmacology (12.2)]. 7 DRUG INTERACTIONS

Table 1 includes clinically significant drug interactions with DILAUDID INJECTION. TABLE 1. Clinically Significant Drug Interactions with DILAUDID INJECTION

Benzodiazepines and other Central Nervous System Depressants (CNS)

enzodiazepines and other G	Lentral Nervous System Depressants (CNS)			
Clinical Impact:	Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.			
Intervention:				
Examples:	Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.			
erotonergic Drugs				
Clinical Impact:	The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome			
Intervention:	If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue DILAUDID INJECTION if serotonin syndrome is suspected.			
Examples:	Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).			
Ionoamine Oxidase Inhibitors (MAOIs)				
Clinical Impact:	MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2)]. If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.			
Intervention:	The use of DILAUDID INJECTION is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.			
Examples:	phenelzine, tranylcypromine, linezolid			
	nd Partial Agonist Opioid Analgesics			
Clinical Impact:	May reduce the analgesic effect of DILAUDID INJECTION and/or precipitate withdrawal syndrome.			
Intervention:	Avoid concomitant use.			
Examples:	butorphanol, nalbuphine, pentazocine, buprenorphine			
Iuscle Relaxants				
Clinical Impact:	Hydromorphone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.			
Intervention:	Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of DILAUDID INJECTION and/or the muscle relaxant as necessary.			
iuretics				
Clinical Impact:	Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.			
Intervention:	Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.			
nticholinergic Drugs				
Clinical Impact:	The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.			
Intervention:	Monitor patients for signs of urinary retention or reduced gastric motility when DILAUDID INJECTION is used concomitantly with anticholinergic drugs.			

## 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Clinical Considerations

and Precautions (5.3)].

Labor or Deliverv

Data

Animal Data

Fetal/Neonatal Adverse Reactions

for signs of excess sedation and respiratory depression.

of malformations or embryotoxicity reported.

or embryotoxicity reported.

**Risk Summary** 

Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome [see Warnings and Precautions (5.3)]. There are no available data with DILAUDID injection in pregnant women to inform a drug-associated risk for major birth defects and miscarriage

In animal reproduction studies, reduced postnatal survival of pups, and decreased body weight were noted following oral treatment of pregnant rats with hydromorphone during gestation and through lactation at doses 0.8 times the human daily dose of 24 mg/day (HDD), respectively. In published studies, neural tube defects were noted following subcutaneous injection of hydromorphone to pregnant hamsters at doses 6.4 times the HDD and soft tissue and skeletal abnormalities were noted following subcutaneous continuous infusion of 3 times the HDD to pregnant mice. No malformations were noted at 4 or 40.5 times the HDD in pregnant rats or rabbits, respectively [see Data]. Based on animal data, advise pregnant women of the potential risk to a fetus.

Serotonin syndrome; Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see Warnings

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in peopates An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. DII AUDID INJECTION is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including DILAUDID INJECTION, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor

Pregnant rats were treated with hydromorphone hydrochloride from Gestation Day 6 to 17 via oral gavage doses of 1, 5, or 10 mg/kg/day (0.4, 2, or 4 times the HDD of 24 mg based on body surface area, respectively). Maternal toxicity was noted in all treatment groups (reduced food consumption and body weights in the two highest dose groups). There was no evidence

Pregnant rabbits were treated with hydromorphone hydrochloride from Gestation Day 7 to 19 via oral gayage doses of 10.25. or 50 mg/kg/day (8.1, 20.3, or 40.5 times the HDD of 24 mg based on body surface area, respectively). Maternal toxicity was noted in the two highest dose groups (reduced food consumption and body weights). There was no evidence of malformations



# DILAUDID<sup>®</sup> INJECTION

# DILAUDID<sup>®</sup> INJECTION



In a published study, neural tube defects (exencephaly and cranioschisis) were noted following subcutaneous administration Treatment of Overdose of hydromorphone hydrochloride (19 to 258 mg/kg) on Gestation Day 8 to pregnant hamsters (6.4 to 87.2 times the HDD of In case of overdose, priorities are the reestablishment of a patent airway and protected airway and institution of assisted or 24 mo/day based on body surface area). The findings cannot be clearly attributed to maternal toxicity. No neural tube defects were noted at 14 mg/kg (4.7 times the human daily dose of 24 mg/day).

malformed ventricles and retina), and skeletal variations (split supraoccipital, checkerboard and split sternebrae, delayed depression secondary to hydromorphone overdose. ossification of the paws and ectopic ossification sites) were observed at doses 3 times the human dose of 24 mg/day based on body surface area. The findings cannot be clearly attributed to maternal toxicity.

Increased pup mortality and decreased pup body weights were noted at 0.8 and 2 times the human daily dose of 24 mg in a oral gavage doses of 0, 0.5, 2, or 5 mg/kg/day (0.2, 0.8, or 2 times the HDD of 24 mg based on body surface area, respectively). Maternal toxicity (decreased food consumption and body weight gain) was also noted at the two highest doses tested.

8.2 Lactation

<u>Risk Summary</u>

Low levels of opioid analgesics have been detected in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DILAUDID INJECTION and any potential adverse effects on the breastfed infant from DILAUDID INJECTION or from the underlying maternal condition.

Clinical Considerations

Monitor infants exposed to DILAUDID INJECTION through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of hydromorphone is stopped, or when breast-feeding is stoppe

8.3 Females and Males of Reproductive Potential

Infertility

Chronic use of opioids may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions (6), Clinical Pharmacology (12.2), Nonclinical Toxicology (13.1)]. 8.4 Pediatric Use

The safety and effectiveness of DILAUDID INJECTION in pediatric patients has not been established.

8.5 Geriatric Use

Elderly patients (aged 65 years or older) may have increased sensitivity to hydromorphone. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therap

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of DILAUDID INJECTION slowly in geriatric patients and monitor closely for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.5)].

Hydromorphone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should a buffer to maintain a pH between 3.5 and 5.5. be taken in dose selection, and it may be useful to monitor renal function.

#### 8.6 Hepatic Impairment

The pharmacokinetics of hydromorphone are affected by hepatic impairment. Due to increased exposure of hydromorphone, patients with moderate hepatic impairment should be started at one-fourth to one-half the recommended starting dose depending on the degree of hepatic dysfunction and closely monitored during dose titration. The pharmacokinetics of hydromorphone in patients with severe hepatic impairment has not been studied. A further increase in C<sub>max</sub> and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose [see Clinical Pharmacology (12.3].

#### 8.7 Renal Impairment

The pharmacokinetics of hydromorphone are affected by renal impairment. Start patients with renal impairment on one-fourth effects of this drug. to one-half the usual starting dose depending on the degree of impairment. Patients with renal impairment should be closely 12.2 Pharmacodynamics monitored during dose titration [see Clinical Pharmacology (12.3)].

#### 9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

DILAUDID INJECTION contains hydromorphone, which is a Schedule II controlled substance.

9.2 Abuse

DILAUDID INJECTION contains hydromorphone hydrochloride, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. DILAUDID INJECTION can be abused and is subject to misuse, addiction, and criminal diversion [see Warnings and Precautions (5.1)].

All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and Effects on the Cardiovascular System includes a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

"Drug-seeking" behavior is very common in persons with substance use disorders. Drug-seeking tactics include, emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of Effects on the Endocrine System prescriptions, tampering of prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare providers. "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

DILAUDID INJECTION, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful recordkeeping of prescribing information, including quantity, frequency, and renewal requests as required by state and federal law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Risks Specific to Abuse of DILAUDID INJECTION

Abuse of DILAUDID INJECTION poses a risk of overdose and death. The risk is increased with concurrent use of DILAUDID INJECTION with alcohol and other central nervous system depressants

Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

### 9.3 Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence results in withdrawal symptoms after abrupt discontinuation of a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.

DILAUDID INJECTION should not be abruptly discontinued in a physically-dependent patient [see Dosage and Administration (2.6)]. If DILAUDID INJECTION is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Some or all of the following can characterize this syndrome; restlessness, lacrimation, rhinorrhea, vawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)].

10 OVERDOSAGE

Clinical Presentation


Acute overdose with DILAUDID INJECTION can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis, rather than miosis, may be seen with hypoxia in overdose situations [see Clinical Pharmacology (12.2)].

controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of irculatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. In a published study, CF-1 mice were treated subcutaneously with continuous infusion of 7.5, 15, or 30 mg/kg/day The opioid antagonists, naloxone or nalmefene are specific antidotes to respiratory depression resulting from opioid overdose. hydromorphone hydrochloride (1.5, 3, or 6.1 times the human daily dose of 24 mg based on body surface area) via implanted For clinically significant respiratory or circulatory depression secondary to hydromorphone overdose, administer an opioid osmotic pumps during organogenesis (Gestation Days 7 to 10). Soft tissue malformations (cryptorchidism, cleft palate, antagonist. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory

Because the duration of opioid reversal is expected to be less than the duration of hydromorphone in DILAUDID INJECTION. carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information. study in which prequant rats were treated with hydromorphone hydrochloride from Gestation Day 7 to Lactation Day 20 via In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.

#### DESCRIPTION

DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid agonist. DILAUDID INJECTION is available as a sterile, aqueous solution in clear and colorless single-dose prefilled syringes for slow intravenous, subcutaneous, or intramuscular administration, Each 1 mL of solution contains 1 mg or 2 mg of hydromorphone hydrochloride. The chemical name of DILAUDID is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 321.80. Its molecular formula is  $C_{17}H_{19}NO_3$  HCl, and it has the following chemical structure:



Hydromorphone hydrochloride is a white or almost white crystalline powder that is freely soluble in water, very slightly soluble in ethanol (96%), and practically insoluble in methylene chloride The inactive ingredients in DILAUDID (hydromorphone hydrochloride) include: 0.2% sodium citrate and 0.2% citric acid added as

#### CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

For more information concerning this drug, please call Fresenius Kabi USA, LLC at 1-800-551-7176. Hydromorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-PROTECT FROM LIGHT. receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is FDA-1088 or www.fda.gov/medwatch. no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. adverse reactions, including respiratory and CNS depression Safety and Handling Instructions The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds Access to drugs with a potential for abuse such as DILAUDID INJECTION presents an occupational hazard for addiction in the **KABI** with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic health care industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect health care workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by health care providers. Lake Zurich, IL 60047

Effects on the Central Nervous System Hydromorphone produces respiratory depression by direct effect on brain stem respiratory centers. The respiratory depression Serotonin Syndrome involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation

Hydromorphone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may medications, [see Drug Interactions (7)]. be seen due to hypoxia in overdose situations.

#### Effects on the Gastrointestinal Tract and Other Smooth Muscle

dromorphone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient evations in serum amvlase.

Hydromorphone produces peripheral vasodilation which may result in orthostatic hypotension or syncope, manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, and sweating and/or orthostatic a precipitate.

CAUTION: Certain glass syringes may malfunction, break or clog when connected to some Needleless Luer Access Devices (NLADs) and needles. This syringe has a larger internal syringe tip and an external collar (luer collar). The external collar must remain attached to the syringe. Data show that the syringe achieves acceptable connections with the BD Eclipse™ Needle and the Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [see Terumo SurGuard2™ Safety Needle and with the following non-center post NLADs; Alaris SMARTSITE™, B-Braun ULTRASITE™ Adverse Reactions (6)]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin BD-Q SYTE™, Maximum MAX PLUS™, and B-Braun SAFSITE™. The data also show acceptable connections are achieved to and glucago the center post ICU Medical CLAVE™. However, spontaneous disconnection of this glass syringe from needles and NLADs with hronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest leakage of drug product may occur. Assure that the needle or NLAD is securely attached before beginning the injection. Visually Abuse and addiction are separate and distinct from physical dependence and tolerance. Healthcare providers should be aware as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome inspect the glass syringe-needle or glass syringe –NLAD connection before and during drug administration. Do not remove the of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence clear plastic wrap around the external collar. (See Figure 1)

adal hormone levels have not been adequately controlled for in studies conducted to date [see Adverse Reactions (6)]. Effects on the Immune System

Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive. Concentration—Efficacy Relationship

The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been eviously treated with potent agonist opioids. The minimum effective analgesic concentration of hydromorphone for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the evelopment of analgesic tolerance [see Dosage and Administration (2.1, 2.2)]. Concentration–Adverse Reaction Relationships

adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see Dosage and Administration (2.1, 2.2]]. 12.3 Pharmacokinetics

#### Distributio

At therapeutic plasma levels, hydromorphone is approximately 8-19% bound to plasma proteins. After an intravenous bolus dose, the steady state of volume of distribution [mean (%CV)] is 302.9 (32%) liters. Elimination

intravenous dose is about 2.3 hours.

Metabolism

to hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.

Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites. Special Populations

#### Hepatic Impairment

After oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets), mean exposure to hydromorphone (C<sub>max</sub> and AUC∞) is increased 4-fold in patients with moderate (Child-Pugh Group B) hepatic impairment compared with sufficiency with normal hepatic function. Patients with moderate hepatic impairment should be started at one-fourth to one-half the recommended starting dose and closely monitored during dose titration. The

# There is a relationship between increasing hydromorphone plasma concentration and increasing frequency of dose-related opioid

The systemic clearance is approximately 1.96 (20%) liters/minute. The terminal elimination half-life of hydromorphone after an

Hydromorphone is extensively metabolized via glucuronidation in the liver, with greater than 95% of the dose metabolized

pharmacokinetics of hydromorphone in patients with severe hepatic impairment has not been studied. A further increase in 4. Perform visual inspection on the syringe by verifying: and AUC of hydromorphone in this group is expected and should be taken into consideration when selecting a starting dose *lsee Use in Specific Populations (8.6)*]. Renal Impairment

The pharmacokinetics of hydromorphone following an oral administration of hydromorphone at a single 4 mg dose (2 mg hydromorphone immediate-release tablets) are affected by renal impairment. Mean exposure to hydromorphone (C AUC0- $\infty$ ) is increased by 2-fold in patients with moderate (CLcr = 40 - 60 mL/min) renal impairment and increased by 4-fold in patients with severe (CLcr< 30 mL/min) renal impairment compared with normal subjects (CLcr> 80 mL/min). In addition, in patients with severe renal impairment, hydromorphone appeared to be more slowly eliminated with a longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr). Start patients with renal impairment on one-fourth to one-half the usual starting dose depending on the degree of impairment. Patients with renal impairment should be closely monitored during dose titration [see Use in Specific Populations (8.7)]. Geriatric Population

In the geriatric population, age has no effect on the pharmacokinetics of hydromorphone.

Sex has little effect on the pharmacokinetics of hydromorphone. Females appear to have a higher C<sub>max</sub> (25%) than males with comparable AUC0-24 values. The difference observed in C<sub>max</sub> may not be clinically relevant.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**Carcinogenesi** 

Long term studies in animals to evaluate the carcinogenic potential of hydromorphone have not been conducted. Mutagenesis

lydromorphone was positive in the mouse lymphoma assay in the presence of metabolic activation, but was negative in the mouse lymphoma assay in the absence of metabolic activation. Hydromorphone was not mutagenic in the in vitro bacterial reverse mutation assay (Ames assay). Hydromorphone was not clastogenic in either the in vitro human lymphocyte chromosome aberration assay or the in vivo mouse micronucleus assay.

### Impairment of Fertility

Reduced implantation sites and viable fetuses were noted at 2.1 times the human daily dose of 32 mg/day in a study in which female rats were treated orally with 1.75, 3.5, or 7 mg/kg/day hydromorphone hydrochloride (0.5, 1.1, or 2.1 times a human daily dose of 24 mg/day (HDD) based on body surface area) beginning 14 days prior to mating through Gestation Day 7 and male rats were treated with the same hydromorphone hydrochloride doses beginning 28 days prior to and throughout mating.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

DILAUDID INJECTION (hydromorphone hydrochloride) is supplied in clear and colorless single-dose prefilled syringes. Each singledose prefilled syringe of sterile, aqueous solution contains 0.5 mg, 1 mg or 2 mg hydromorphone hydrochloride with 0.2% sodium citrate and 0.2% citric acid solution. DILAUDID INJECTION contains no added preservative and is supplied as follows:

roduct Code	Unit of Sale	Strength	Each
71905	NDC 76045-009-05 Unit of 24	0.5 mg/0.5 mL	NDC 76045-009-03 0.5 mL single-dose prefilled syringe
71910	NDC 76045-009-10 Unit of 24	1 mg/mL	NDC 76045-009-00 1 mL single-dose prefilled syringe
71010	NDC 76045-010-10 Unit of 24	2 mg/mL	NDC 76045-010-00 1 mL single-dose prefilled syringe

# 17 PATIENT COUNSELING INFORMATION

Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant 451535D administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right Dilaudid is a licensed trademark of Purdue Pharma L.P. away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic


Constipatio

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention *[see Adverse Reactions (6)]*.

Healthcare professionals can telephone Fresenius Kabi USA, LLC at 1-800-551-7176 for information or to report adverse events on this product.

### INSTRUCTIONS FOR USE

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if color is darker than pale yellow, if it is discolored in any other way or if it contains



- 1. Inspect the outer packaging (blister pack) by verifying:
  - blister integrity
- drug name
- drug strength dose volume
- route of administration

Figure 2

- expiry date to be sure that the drug has not expired
- sterile field applicability
- Do not use if package has been damaged.
- 2. Peel open the paper (top web) of the outer packaging that displays the product information to access the syringe. Do not pop svringe through. (See Figure 2)

3. Bend the plastic part of the outer packaging (thermoform) so as to present the plunger rod for syringe removal.

- absence of syringe damage absence of external particles
- absence of internal particles
- proper drug color
- expiration date to be sure that the drug has not expired
- drug name - drug strength
- dose volume
- route of administration
- integrity of the plastic wrap around the external collar

5. Do not remove plastic wrap around the external collar. Push plunger rod slightly to break the stopper loose while tip cap is still on

6. Do not remove plastic wrap around the external collar. Remove tip cap by twisting it off. (See Figure 3) Figure 3



7. Discard the tip cap

8. Expel air bubble

Adjust dose into sterile material (if applicable)

10. Connect the syringe to appropriate injection connection depending on route of administration. Before injection, ensure that the syringe is securely attached to the needle or NLAD.

11. Depress plunger rod to deliver medication. Ensure that pressure is maintained on the plunger rod during the entire

12. Remove syringe from NLAD (if applicable) and discard into appropriate receptacle. If delivering the medication with a needle, to prevent needle stick injuries, do not recap needle.

NOTES:

- All steps must be done sequentially
- Do not autoclave syringe
- Do not use this product on a sterile field
- Do not introduce any other fluid into the syringe at any time
- This product is for single dose only



www.fresenius-kabi.com/us Rev. 10/2018